Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 2, 1996, Pages 157-163

  Hartley, M G ^a   Hudson, M J ^a   Swarbrick, E T ^b   Grace, R H ^b   Gent, A E ^c   Hellier, M D ^d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NEW CROSS HOSPITAL   (United Kingdom)

^c SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^d PRINCESS MARGARET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SALAZOSULFAPYRIDINE;

ARTICLE; BACTERIAL FLORA; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA; ULCERATIVE COLITIS;

EID: 0029996229     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.723115000.x     Document Type: Article

References (21)

1. Kirsner JB, Shorter RG. Recent developments in "non-specific" inflammatory bowel disease. (In 2 parts.) N Engl J Med 1982; 306: 775-85; 837-48.
2. Allan RN. Ulcerative colitis: Summary of medical treatment including symptomatic relief. In: Allan RN, Keighley MRB, Alexander-Williams J, Hawkins C, eds. Inflammatory Bowel Disease. Edinburgh: Churchill Livingstone, 1983; 232-9.
3. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181: 555-62.
4. Gorbach SL, Nahas L, Plaut AG, Weinstein L, Paterson JF, Levitan R. Studies of intestinal microflora: V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of the disease and chemotherapy. Gastroenterology 1968; 54: 575-87.
5. Cooke EM. Faecal flora of patients with ulcerative colitis during treatment with salicylazosulphapyridine. Gut 1974; 15: 143-6.
6. West B, Lendrum R, Hill MJ, Walker G. Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut 1974; 15: 960-5.
7. Leijonmark CE, Benno P, Carlstedt-Duke B, et al. The function of the intestinal microflora in patients with ulcerative colitis before and after colectomy. Scand J Gastroenterol 1990; 25: 585-93.
8. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the activity moiety of sulphasalazine. Lancet 1977; ii: 892-5.
9. Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients idiopathic proctitis: A study to determine the active therapeutic moiety of salicylazosulphapyridine. Gut 1980; 21: 632-5.
10. Baron JH, Connel AM, Lennard-Jones JE, Avery Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; i: 1094-6.
11. Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 481-95.
12. Riley SA, Turnberg LA. Sulphasalazine and the amino-salicylates in the treatment of ulcerative colitis. Q J Med 1990; 278: 551-62.
13. Hanauer SB. Advances in drug treatment: New salicylates. In: Anagnostides AA, Hodgson HJF, Kirsner JB, eds. Inflammatory Bowel Disease. London: Chapman and Hall Medical, 1991; 287-308.
14. Järnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994; 35: 1155-8.
15. Marks CG, Hawley PR, Peach SL, Drasar BS, Hill MJ. The effects of phthalylsulphathiazole on the bacteria of the colonic mucosa and intestinal contents as revealed by the examination of surgical samples. Scand J Gastroenterol 1979; 14: 891-6.
16. Hudson MJ, Hill MJ, Elliott PR, Berghouse LM, Burnham WR, Lennard-Jones JE. The microbial flora of the rectal mucosa and faeces of patients with Crohn's disease before and during antimicrobial chemotherapy. J Med Microbiol 1984; 18: 335-45.
17. Hartley MG, Hudson MJ, Swarbrick ET, et al. The rectal mucosa-associated microflora in patients with ulcerative colitis. J Med Microbiol 1992; 36: 96-103.
18. Cooke EM, Ewins SP, Hywel-Jones J, Lennard-Jones JE. Properties of strains of E. coli carried in different phases of ulcerative colitis. Gut 1974; 15: 143-6.
19. Burke DA, Axon ATR. Ulcerative colitis and E. coli with adhesive properties. J Clin Pathol 1987; 40: 782-6.
20. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992; 33: 646-50.
21. Hartley MG, Hudson MJ, Swarbrick ET, Gent AE, Hellier MD, Grace RH. The adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis. Gut 1993; 34: 63-7.